Professor Lars Nielson and his team at the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology are utilizing stem cells to develop a treatment for patients at risk for chemotherapy-induced neutropenia (CIN). Neutropenia is caused by the lack of white blood cells. By differentiating stem cells into white blood cells, the treatment reduces the ‘risk’ period of infection and fever following chemotherapy.
Current treatments involve the administration of granulocyte colony-stimulating factor (G-CSF), which aims to increase the number of white blood cells by stimulating their production in the bone marrow of the patient. However, bone marrow is significantly reduced after chemotherapy thereby limiting the ability to replenish white blood cells. Professor Nielson’s approach is to retrieve stem cells from umbilical cord blood and culture them to produce an abundant supply of white blood cells which can then be administered to patients with a simple transfusion bag immediately following chemotherapy. Clinical trials are expected to commence soon.
Advances in regenerative medicine will accelerate stem cell applications to treat a broader variety of infection and disease. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.